Stockreport

Novo Nordisk Weighs UBT251 Triple Agonist Against Semaglutide In Next Trials [Yahoo! Finance]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF Novo Nordisk (CPSE:NOVO B) and United Laboratories report phase 2 data from China for UBT251 in type 2 diabetes. UBT251, a triple agonist, shows greater reductions in [Read more]